Genzyme files applications for approval of Mozobil in the US, European Union
Genzyme Corp. Tuesday said it has filed applications for the approval of Mozobil, in the treatment of patients with lymphoma and multiple myeloma, in the US and the European Union.
It is rumoured that multinational drugmaker Sanofi-Aventis is to acquire US-based biotechnology company Genzyme, a manufacturer of vaccines for genetic disorders and producer of drugs such as Cerezyme, a treatment for Gaucher's disease, and Fabrazyme, for Fabry disease.